Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

More Registry Data Show Post-TAVI Benefits With Sentinel but No Stroke Impact

News Conference News TCT 2024

The ADAPT-TAVR Trial

March 08, 2023

Presentation TCT 2022

TCT 331: Predictors of Valvular and Perivalvular Thrombosis and Relations of Neurological Outcomes after TAVR: ADAPT-TAVR Substudy

Presenter: Yeonwoo Choi

September 19, 2022

Presentation TCT 2022

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

Presenter: Mijin Kim

September 18, 2022

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Todd Neale

April 05, 2022

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

News Conference News STS 2019

TAVR More Prevalent in Highly Competitive Hospital Markets

Yael L. Maxwell

February 04, 2019

Video

» Interview

A Randomized ADAPT-TAVR Trial: Edoxaban Versus Dual Antiplatelet Therapy for Valve Thrombosis and Cerebral Thromboembolism After Transcatheter Aortic-Valve Replacement

May 4, 2022

Video

» Interview

Beyond the Data: ADAPT-TAVR

April 6, 2022

Advertisement

More Registry Data Show Post-TAVI Benefits With Sentinel but No Stroke Impact

The ADAPT-TAVR Trial

TCT 331: Predictors of Valvular and Perivalvular Thrombosis and Relations of Neurological Outcomes after TAVR: ADAPT-TAVR Substudy

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

TAVR More Prevalent in Highly Competitive Hospital Markets

A Randomized ADAPT-TAVR Trial: Edoxaban Versus Dual Antiplatelet Therapy for Valve Thrombosis and Cerebral Thromboembolism After Transcatheter Aortic-Valve Replacement

Beyond the Data: ADAPT-TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content